Medtech Insight is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CYTOGEN PROSTASCINT INITIAL USE WILL BE RESTRICTED TO SITES CERTIFIED BY ACNP; SCAN FOR METASTATIC PROSTATE CANCER IS COMPLEMENTARY TO OTHER TESTS

This article was originally published in The Gray Sheet

Executive Summary

Cytogen plans to restrict initial availability of its prostate cancer imaging agent ProstaScint (capromab pendetide) to sites certified by the American College of Nuclear Physicians. "We don't think it is appropriate for sites to use this product without training," Cytogen VP-Medical Affairs Robert Maguire, MD, told FDA's Medical Imaging Drugs Advisory Committee July 22. Cytogen will offer a "Partners in Excellence" training program for use of ProstaScint, he added.
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT006416

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel